<DOC>
	<DOCNO>NCT00365326</DOCNO>
	<brief_summary>This phase I clinical trial evaluate safety efficacy intra-coronary injection AC133 select autologous marrow-derived stem cell patient chronic coronary artery occlusion . A clinical study determine therapeutic potential marrow-derived stem cell adjunct therapy current standard therapy CAD warrant . The current initiative investigate model chronic myocardial ischemia ( 1 ) determine whether intra-coronary injection select autologous marrow-derived AC133 stem cell reasonably safe use human ( 2 ) treatment show improvement coronary perfusion , assess use non-invasive imaging . This study structure evaluate feasibility safety autologous AC133+ bone marrow-derived stem cell via intra-coronary injection document ischemic viable myocardial zone via establish collateral vessel . The epicardial vessel normally supply ischemic zone must 100 % chronically occlude consider non-revascularizable percutaneous mean .</brief_summary>
	<brief_title>Safety Efficacy Autologous , Intracoronary Stem Cell Injections Total Coronary Artery Occlusions</brief_title>
	<detailed_description>This study compose one phase . The objective Phase I assess safety feasibility perform escalate dos autologous AC133+ select bone marrow-derived stem cell intracoronary infusion via epicardial vessel supply collateral flow area viable ischemic myocardium distribution chronic totally occluded vessel . Additionally , focus assessment benefit achieve infusion stem cell subsequent angiogenesis 6 month observe . Potential candidate patient know total occlusion epicardial vessel , document chronically ischemic territory supply collateral conduit . Secondary Objectives include : 1 . Improvement ETT determine : total exercise duration 6 month ETT second time : onset angina , one mm ST depression , onset angina one mm ST depression ( whichever occurs first ) 2 . Reduction area ischemia evaluate nuclear ( sestamibi ) stress image exercise pharmacologic stress . 3 . Improvement viability within chronically ischemic zone measure nuclear ( sestamibi ) stress image . 4 . Improvement angina per Angina Questionnaire ( The Seattle Angina Questionnaire ) 7 , 14 , 30 , 90 , 180 , 365 day . 5 . Major adverse cardiac event ( MACE ) assessment ( composite endpoint include cardiac death , myocardial infarction , ischemia-driven target vessel revascularization , CABG , CVA , rehospitalization angina ) , MACE definition : Myocardial Infarction ( All ST segment elevation MIs diagnose electrocardiogram staff cardiologist non-ST segment elevation MIs define elevation cardiac enzyme marker per hospital laboratory guideline ) Cerebral Vascular Accidents ( e.g. , acute neurological event ) . 6 . Concomitant Medication usage ( e.g. , change utilization PRN sublingual nitroglycerin angina ) 7 . ECG change day discharge , 7 , 14 , 30 , 90 , 180 , 365 day . 8 . Functional capacity ( e.g. , exercise duration ( time ) change METS achieve treadmill study 6 month follow-up ) . 9 . Echocardiogram assessment leave ventricular ejection fraction regional wall motion abnormality 180 day ( e.g. , change regional wall motion score and/or change leave ventricular ejection fraction ) .</detailed_description>
	<mesh_term>Coronary Occlusion</mesh_term>
	<criteria>1 . The patient must least one region chronically ischemic myocardium formerly perfuse coronary artery 100 % occlude revascularizable conventional percutaneous surgical method . 2 . Wellestablished collateral vessel least 1.5mm luminal diameter coronary angiography chronically ischemic myocardium must identify time diagnostic coronary angiography . 3 . Evidence viable myocardium area supply collateral conduit intend stem cell infusion must demonstrate nuclear ( sestamibi ) stress image . 4 . Left ventricular ejection fraction &gt; 45 % per 2D echocardiogram . 5 . Patient must experience class II IV angina define Canadian Cardiovascular Society ( CCS ) . 6 . Patient follow investigate team 12 month followup period . 7 . The patient must least 18 year age sign informed consent . 8 . If patient female childbearing potential , pregnancy test negative . Patients meet follow exclusion criterion exclude study : 1 . Patient coronary lesion amenable percutaneous coronary intervention include brachytherapy , CABG indicate . 2 . Any contraindication cardiac catheterization percutaneous coronary intervention per institutional guideline . 3 . Any contraindication bone marrow aspiration per institutional guideline . 4 . Myocardial infarction within previous 3 month . 5 . Documented bleeding diathesis . 6 . Known malignancy involve hematopoietic/lymphoid system . 7 . Patients baseline ECG abnormality would hinder interpretation baseline ECG uninterpretable ischemia ( e.g. , leave bundle branch block , leave ventricular hypertrophy strain pattern , WolffParkinsonWhite syndrome ) . 8 . Patients severe comorbidities include renal failure ( serum creatinine &gt; 2.0 ) . 9 . Anticipated unavailability followup visit secondary psychological social reason . 10 . NYHA class III IV congestive heart failure 11 . Anemia hemoglobin concentration &lt; 8 mg/dl 12 . Thrombocytopenia platelet count &lt; 100 x 103</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>AC133</keyword>
	<keyword>coronary</keyword>
	<keyword>bone marrow</keyword>
	<keyword>autologous</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>